Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares OutstandingShort-Term Debt repayments
Ratios

BioNexus Gene Lab (BGLC) Other Gross PP&E Adjustments (2019 - 2025)

Historic Other Gross PP&E Adjustments for BioNexus Gene Lab (BGLC) over the last 7 years, with Q3 2025 value amounting to $2.4 million.

  • BioNexus Gene Lab's Other Gross PP&E Adjustments rose 9686.69% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 9686.69%. This contributed to the annual value of $2.3 million for FY2024, which is 158.85% up from last year.
  • BioNexus Gene Lab's Other Gross PP&E Adjustments amounted to $2.4 million in Q3 2025, which was up 9686.69% from $2.3 million recorded in Q2 2025.
  • BioNexus Gene Lab's Other Gross PP&E Adjustments' 5-year high stood at $2.4 million during Q3 2025, with a 5-year trough of $1.2 million in Q3 2024.
  • Its 5-year average for Other Gross PP&E Adjustments is $2.1 million, with a median of $2.2 million in 2022.
  • As far as peak fluctuations go, BioNexus Gene Lab's Other Gross PP&E Adjustments skyrocketed by 1526718.33% in 2021, and later crashed by 4690.77% in 2024.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Other Gross PP&E Adjustments stood at $2.2 million in 2021, then crashed by 33.04% to $1.5 million in 2022, then surged by 55.39% to $2.3 million in 2023, then grew by 1.59% to $2.3 million in 2024, then grew by 2.83% to $2.4 million in 2025.
  • Its Other Gross PP&E Adjustments stands at $2.4 million for Q3 2025, versus $2.3 million for Q2 2025 and $2.3 million for Q1 2025.